Neuron BPh has applied for two patents on compounds showing neuroprotective and anti-epileptic activity
During the first semester of 2009 Neuron BPh applied for two new patents on the anti-epileptic and neuroprotective activity of several compounds developed by the company’s biopharmaceutical division, Neuron BioPharma.
The compounds’ neuroprotective activities were initially tested by studying the effects induced when they were administered to mice and fish, the results of which pointed to the fact that they may offer treatment against neurodegenerative diseases, such as Alzheimer’s. The company’s researchers have also tested the compounds’ anti-epileptic activity and their modulatory effect on cholesterol levels. Once their therapeutic activity has been thoroughly tested on the company’s animal model, it will begin in 2010 to study this activity on humans, thus, entering into Phases I and II of clinical development.
Further to this, Neuron BPh has entered into negotiations with several pharmaceutical companies to market and commercialize these compounds.
These two new patents join the seven patents previously owned by the company, all of which are the result of research projects developed since the founding of Neuron BPh.